AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Stock indices move on earnings, policy changes, and macro data. This intro covers the core catalysts that drive daily swings.
23,761 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Tuesday brought a notable standout in the banking space as JPMorgan Chase topped market momentum. This piece breaks d...
UiPath edges higher as investors monitor its agentic automation strategy ahead of earnings. This analysis breaks down...
A single insider move often sparks headlines, but context matters. This article digs into what this credo insider's s...
PayPal stock has been grabbing headlines with a rapid rise tied to buyout chatter and a strategic turnaround. This gu...
Bloom Energy has surged 497% over the past year, shaking up portfolios and headlines. This guide breaks down what the...
Sionna Therapeutics has surged 144% over the past year, drawing attention from growth-minded investors. This article ...
A multibillion-dollar air defense push in Greece is drawing investor attention to Lockheed Martin and other defense c...
A senior Rogers Corp. executive sold 830 shares for about $113,000, sparking questions about what it means for the st...
A dramatic 40% jump for Dyne Therapeutics has investors watching closely as a biotech-focused fund disclosed a sizabl...
Oklo faces a pivotal moment after July. This piece explains a single catalyst investors should watch, the potential s...
Looking to grow $1,000 into something bigger over time? This guide highlights three broadly understood stocks that fi...